Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012 [Studio clinico di fase II a singolo braccio di trattamento con tremelimumab, un anticorpo monoclonale umano, in monoterapia in pazienti con mesotelioma maligno non resecabile. Codice dello Studio]

Next Previous
X
Search
Trial Profile

A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012 [Studio clinico di fase II a singolo braccio di trattamento con tremelimumab, un anticorpo monoclonale umano, in monoterapia in pazienti con mesotelioma maligno non resecabile. Codice dello Studio]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tremelimumab (Primary)
  • Indications Malignant-mesothelioma
  • Focus Pharmacokinetics; Therapeutic Use

    • Most Recent Events

    • 02 Mar 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 09 Apr 2014 Pooled pharmacokinetic analysis presented at the 105th Annual Meeting of the American Association for Cancer Research.
    • 11 Aug 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2012-002762-12).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top